Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test model flag dangerous myelosuppression before it strikes?

NCT ID NCT07819656

Diagnosis Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

Researchers are evaluating a dynamic risk prediction model for severe myelosuppression in adults with nasopharyngeal carcinoma who receive systemic anticancer treatment. The model estimates the risk of grade 3 or higher anemia, low platelets, or low white blood cells during therapy. About 1,782 patients will give routine clinical and lab data before each treatment cycle, and doctors will follow them through treatment and for 28 days after. The study observes whether the model predicts accurately across multiple centers; it does not use predictions to change patient care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the model predicts severe myelosuppression well, doctors could one day use routine blood tests to flag high-risk patients earlier and adjust monitoring or supportive care.
What could go wrong
This is an observational study, so it cannot prove the model changes outcomes. The model may not predict accurately across different hospitals, and predictions will not guide treatment during the study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,782 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with histologically confirmed nasopharyngeal carcinoma who require systemic anticancer treatment according to routine clinical practice will be prospectively enrolled from participating study centers.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntary provision of written informed consent. * Age ≥18 years. * Histologically confirmed nasopharyngeal carcinoma. * Patients who, in the judgment of the treating physician, require systemic anticancer treatment. Exclusion Criteria: * Presence of other uncontrolled serious diseases, including unstable cardiac disease requiring treatment, poorly controlled diabetes mellitus (fasting blood glucose \>1.5 times the upper limit of normal), psychiatric disorders, or a history of severe allergy. * Considered unsuitable for participation in the study by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myelosuppression are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myelosuppression Nasopharyngeal carcinoma (NPC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.